Skip to content
value.today

Synlogic, Inc.: peers

Change the peers

Synlogic, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Synlogic, Inc., Aligos Therapeutics, Inc., Provectus Biopharmaceuticals Inc., Alaunos Therapeutics, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Synlogic, Inc., Kalaris Therapeutics, Inc., Aligos Therapeutics, Inc., Biomea Fusion, Inc., Instil Bio, Inc., Provectus Biopharmaceuticals Inc., Alaunos Therapeutics, Inc., Tevogen Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureSynlogic, Inc.base
SYBX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Kalaris Therapeutics, Inc.
KLRS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Aligos Therapeutics, Inc.
ALGS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Biomea Fusion, Inc.
BMEA · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Instil Bio, Inc.
TIL · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Provectus Biopharmaceuticals Inc.
PVCT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Alaunos Therapeutics, Inc.
TCRT · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Tevogen Inc.
TVGN · 🇺🇸 US
Percentile in Financial Services
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$44 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8$45 MOct 26, 2026 · Market data6th of 8$43 MAug 1, 2026 · Market data8th of 8$45 MOct 30, 2026 · Market data5th of 8$46 MOct 29, 2026 · Market data3rd of 8$46 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one4th of 8$47 MAug 1, 2026 · Market data1st of 8$47 MOct 14, 2026 · Market data2nd of 8$46 M8 ranked
Revenue (Better neither way: ranked highest first)————$2 MFY2025 · SEC1st of 3————$0 MFY2025 · SEC2nd of 3$0 MFY2025 · SEC3rd of 3——$0 M3 ranked
Net income (Higher is better)$-1 MFY2025 · SEC1st of 8$-43 MFY2025 · SEC6th of 8$-24 MFY2025 · SEC4th of 8$-62 MFY2025 · SEC7th of 8$-71 MFY2025 · SEC8th of 8$-5 MFY2025 · SEC3rd of 8$-4 MFY2025 · SEC2nd of 8$-26 MFY2025 · SEC5th of 8$-25 M8 ranked
Employees (Better neither way: ranked highest first)——107As on 2021 · Profile1st of 367As on June-2020 · Profile2nd of 341December 31, 2025 · Profile3rd of 3————————673 ranked
Growth
Market cap change, 30 days (Higher is better)——-35.5%30 days to Oct 26, 2026 · Market data2nd of 2————-4.0%30 days to Oct 29, 2026 · Market data1st of 2——————-19.7%2 ranked
Revenue growth (Higher is better)————————-39.3%FY2025 · SEConly one with it5th2nd————————————————————-39.3%—
Margins and returns
Return on equity (Higher is better)-8.1%FY2025 · SEC1st of 568th34th————-196.9%FY2025 · SEC4th of 511th5th-152.4%FY2025 · SEC3rd of 516th7th-50.8%FY2025 · SEC2nd of 543rd18th————-198.6%FY2025 · SEC5th of 511th4th————-152.4%5 ranked
Valuation
Price to sales (Better neither way: ranked highest first)————————19.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price——————————————————————
Price to book (Better neither way: ranked highest first)————0.6×price Oct 26, 2026 · Market data2nd of 38th8th0.8×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price1.5×price Oct 30, 2026 · Market data1st of 331st37th0.4×price Oct 29, 2026 · Market data3rd of 35th5th————21.9×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————0.6×3 ranked
Free cash flow yield (Higher is better)————-86.6%price Oct 26, 2026 · Market data2nd of 39th3rd-188.1%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————-121.0%price Oct 29, 2026 · Market data3rd of 35th2nd————-6.3%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-26.6%price Oct 14, 2026 · Market data1st of 35th12th-86.6%3 ranked
Financial strength
Interest cover (Higher is better)————-32.0×FY2025 · SEC2nd of 325th12th————————-13.5×FY2025 · SEC1st of 339th19th-529.0×FY2025 · SEC3rd of 35th2nd————————-32.0×3 ranked
Scorecard
Scorecard (Higher is better)3 of 8FY2025 · Scorecard1st of 83 of 11FY2025 · Scorecard2nd of 82 of 10FY2025 · Scorecard5th of 82 of 11FY2025 · Scorecard6th of 82 of 12FY2025 · Scorecard7th of 82 of 8FY2025 · Scorecard3rd of 82 of 8FY2025 · Scorecard3rd of 80 of 8FY2025 · Scorecard8th of 823% passed8 ranked
Valuation checks (Higher is better)——1 of 4FY2025 · Scorecard2nd of 4——1 of 3FY2025 · Scorecard1st of 41 of 4FY2025 · Scorecard2nd of 4————0 of 4FY2025 · Scorecard4th of 425% passed4 ranked
Growth checks (Higher is better)1 of 2FY2025 · Scorecard1st of 81 of 2FY2025 · Scorecard1st of 81 of 3FY2025 · Scorecard5th of 80 of 2FY2025 · Scorecard6th of 80 of 2FY2025 · Scorecard6th of 81 of 2FY2025 · Scorecard1st of 81 of 2FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard6th of 842% passed8 ranked
Profitability checks (Higher is better)0 of 3FY2025 · Scorecard1st of 80 of 2FY2025 · Scorecard1st of 80 of 3FY2025 · Scorecard1st of 80 of 3FY2025 · Scorecard1st of 80 of 3FY2025 · Scorecard1st of 80 of 2FY2025 · Scorecard1st of 80 of 3FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard1st of 80% passed8 ranked
Financial health checks (Higher is better)1 of 2FY2025 · Scorecard1st of 81 of 3FY2025 · Scorecard5th of 81 of 3FY2025 · Scorecard5th of 81 of 2FY2025 · Scorecard1st of 81 of 2FY2025 · Scorecard1st of 80 of 3FY2025 · Scorecard7th of 81 of 2FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard7th of 842% passed8 ranked
Shareholder returns checks (Higher is better)1 of 1FY2025 · Scorecard1st of 7——0 of 1FY2025 · Scorecard3rd of 70 of 1FY2025 · Scorecard3rd of 70 of 1FY2025 · Scorecard3rd of 71 of 1FY2025 · Scorecard1st of 70 of 1FY2025 · Scorecard3rd of 70 of 1FY2025 · Scorecard3rd of 70% passed7 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)0.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 772.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 724.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 736.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 728.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7——6.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 71.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 724.9%7 ranked
Institutions holding (Better neither way: ranked highest first)12026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7542026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7702026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7——322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7327 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)-0.0 pp2026-Q2 against 2026-Q1 · 13F2nd of 6-5.8 pp2026-Q2 against 2026-Q1 · 13F5th of 6——+1.2 pp2026-Q2 against 2026-Q1 · 13F1st of 6-6.4 pp2026-Q2 against 2026-Q1 · 13F6th of 6——-1.7 pp2026-Q2 against 2026-Q1 · 13F4th of 6-1.6 pp2026-Q2 against 2026-Q1 · 13F3rd of 6-1.7 pp6 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Synlogic, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Kalaris Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Aligos Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Biomea Fusion, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Instil Bio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Provectus Biopharmaceuticals Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Alaunos Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Tevogen Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Revenue growth#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Revenue growth: each company's figure and its percentile in its sector and its country
CompanyRevenue growthIn its sectorIn its country
Synlogic, Inc.———
Kalaris Therapeutics, Inc.———
Aligos Therapeutics, Inc.-39.3%FY2025
5th percentile in Healthcaremedian +10.2%, 734 companies
2nd percentile in USAmedian +6.5%, 3,424 companies
Biomea Fusion, Inc.———
Instil Bio, Inc.———
Provectus Biopharmaceuticals Inc.———
Alaunos Therapeutics, Inc.———
Tevogen Inc.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$4 M$8 M$12 M$16 M2012201420162018202020222024Synlogic, Inc. $0 MAligos Therapeutics, Inc. $2 MProvectus Biopharmaceuticals Inc. $0 MAlaunos Therapeutics, Inc. $0 M

Rank in the group

1st2nd3rd4th20172018201920212022202320242025Synlogic, Inc.: 2nd of 2 in 2017Synlogic, Inc.: 1st of 2 in 2018Synlogic, Inc.: 1st of 2 in 2019Synlogic, Inc.: 1st of 2 in 2021Synlogic, Inc.: 2nd of 3 in 2022Synlogic, Inc.: 2nd of 4 in 2023Synlogic, Inc.: 3rd of 4 in 2024Synlogic, Inc.Kalaris Therapeutics, Inc.: 2nd of 2 in 2019Kalaris Therapeutics, Inc.Aligos Therapeutics, Inc.: 1st of 4 in 2023Aligos Therapeutics, Inc.: 1st of 4 in 2024Aligos Therapeutics, Inc.: 1st of 3 in 2025Aligos Therapeutics, Inc.Provectus Biopharmaceuticals Inc.: 3rd of 3 in 2022Provectus Biopharmaceuticals Inc.: 3rd of 4 in 2023Provectus Biopharmaceuticals Inc.: 2nd of 4 in 2024Provectus Biopharmaceuticals Inc.: 2nd of 3 in 2025Provectus BiopharmaceuticaAlaunos Therapeutics, Inc.: 1st of 2 in 2017Alaunos Therapeutics, Inc.: 2nd of 2 in 2018Alaunos Therapeutics, Inc.: 2nd of 2 in 2021Alaunos Therapeutics, Inc.: 1st of 3 in 2022Alaunos Therapeutics, Inc.: 4th of 4 in 2023Alaunos Therapeutics, Inc.: 3rd of 4 in 2024Alaunos Therapeutics, Inc.: 3rd of 3 in 2025Alaunos Therapeutics, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearSynlogic, Inc.Kalaris Therapeutics, Inc.Aligos Therapeutics, Inc.Biomea Fusion, Inc.Instil Bio, Inc.Provectus Biopharmaceuticals Inc.Alaunos Therapeutics, Inc.Tevogen Inc.
2025——$2 MSEC1st——$0 MSEC2nd$0 MSEC3rd—
2024$0 MSEC3rd—$4 MSEC1st——$1 MSEC2nd$0 MSEC3rd—
2023$3 MSEC2nd—$6 MSEC1st——$1 MSEC3rd$0 MSEC4th—
2022$1 MSEC2nd————$1 MSEC3rd$3 MSEC1st—
2021$2 MSEC1st—————$0 MSEC2nd—
2020————$0 MSEC———
2019$2 MSEC1st$0 MSEC2nd——————
2018$3 MSEC1st—————$0 MSEC2nd—
2017$2 MSEC2nd—————$16 MSEC1st—
2016——————$7 MSEC—
2012——————$1 MSEC—
2011——————$1 MSEC—

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Synlogic, Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Kalaris Therapeutics, Inc.KLRS · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $45 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $45 M (Oct 26, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Aligos Therapeutics, Inc.ALGS · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $43 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $43 M (Aug 1, 2026) · revenue $2 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Biomea Fusion, Inc.BMEA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $45 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $45 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Instil Bio, Inc.TIL · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $46 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $46 M (Oct 29, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Provectus Biopharmaceuticals Inc.PVCT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $46 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $46 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Alaunos Therapeutics, Inc.TCRT · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $47 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $47 M (Aug 1, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Tevogen Inc.TVGN · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $47 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $47 M (Oct 14, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Veru Inc.VERU · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $41 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $41 M (Oct 9, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • INmune Bio, Inc.INMB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $48 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $48 M (Oct 23, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Werewolf Therapeutics, Inc.HOWL · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $48 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $48 M (Oct 27, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Forum Markets, IncorporatedFRMM · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $47 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $47 M (Oct 26, 2026) · revenue $7 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Dogwood Therapeutics, Inc.DWTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $49 M market cap against $44 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $49 M (Oct 15, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.